Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease

Journal of Neuroscience

Volumn 21, Issue 2, 2001, Pages 372-381

  Kawarabayashi, Takeshi ^a,b   Younkin, Linda H ^a   Saido, Takaomi C ^c   Shoji, Mikio ^b   Ashe, Karen Hsiao ^d   Younkin, Steven G ^a  

^a MAYO CLINIC   (United States)

^b GUNMA UNIVERSITY   (Japan)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Cerebrospinal fluid; Neurodegeneration; Plasma; Tg2576 transgenic animal model

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FORMIC ACID; OLIGOMER; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOCHEMISTRY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; SOLUBILITY; TRANSGENIC MOUSE;

EID: 0035863055     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.21-02-00372.2001     Document Type: Article

References (40)

1. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease
2. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo
3. Release of excess amyloid β protein from a mutant amyloid β protein precursor
4. A method for obtaining cerebrospinal fluid from mice
5. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
6. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene
7. Excessive production of amyloid β-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation
8. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
9. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
10. Appearance of sodium dodecyl sulfate-stable amyloid β-protein (Aβ) dimer in the cortex during aging
11. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease
12. Fate of cerebrospinal fluid-borne amyloid β-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries
13. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
14. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
15. Amyloid β protein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43)
16. Quantification of modified amyloid β peptides in Alzheimer disease and down syndrome brains
17. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
18. APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal toss in CA1
19. Amyloid β protein in plasma as a diagnostic marker for Alzheimer's disease
20. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
21. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
22. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: A study in Japan
23. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
24. Accumulation of β-amyloid fibrils in pancreas of transgenic mice
25. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease
26. A familial Alzheimer's disease locus on chromosome 1
27. Amyloid plaque core protein in Alzheimer disease and down syndrome
28. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and down's syndrome
29. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
30. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid
31. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease
32. Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype
33. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease
34. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques
35. Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain
36. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
37. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
38. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants
39. Age-dependent behavioral deficit in a transgenic mouse model of Alzheimer's disease
40. Genetic elevation of plasma amyloid β protein in typical late onset Alzheimer's disease